Adipogen/WY-14643/AG-CR1-3566-M010/10 mg
商品编号：
AG-CR1-3566-M010
品牌：
Adipogen Inc
市场价：
¥400.00
美元价：
240.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Pirinixic acid; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio) acetic acid |
| Product Type | Chemical |
| Properties | |
| Formula | C14H14ClN3O2S |
| MW | 323.8 |
| CAS | 50892-23-4 |
| RTECS | AG2915000 |
| Purity Chemicals | ≥98% |
| Appearance | Off-white solid. |
| Solubility | Soluble in ethanol, DMSO, dimethyl formamide or PBS (pH 7.2). |
| InChi Key | NSHPHXHGRHSMIK-WAXGXQFOSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Potent peroxisome proliferator-activated receptor (PPARα) activator [1, 2, 7, 9]. Activates also PPARγ [4, 7] but not PPARδ [8].
- Potent anti-hypercholesterolemic agent [1].
- Hypolipidemic compound. Lipogenesis inducer [2, 10].
- Tumor promoter [2, 3, 5, 15].
- Causes increased cell proliferation and decreased apoptosis [5].
- Anti-inflammatory. Inhibits NF-κB transcriptional activity and decreases the inflammatory response by reducing the production of inflammatory cytokines (TNF-α, IL1β). Reduces oxidative stress [6, 7, 12, 13].
- Increases fatty acid oxidation [11].
- Directly affects insulin signaling. Increases glucose uptake [12].
- Reviews [5, 11, 14].
Product References
- A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643): A.A. Santilli, et al.; Experientia 30, 1110 (1974)
- The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes: D.E. Moody & J.K. Reddy; Am. J. Pathol. 90, 435 (1978)
- Peroxisome proliferation and hepatocarcinogenesis: M.S. Rao & J.K. Reddy; Carcinogenesis 8, 631 (1987)
- Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids: A. Schmidt, et al.; Mol. Endocrinol. 6, 1634 (1992)
- Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators: R.A. Roberts; Ann. N. Y. Acad. Sci. 804, 588 (1996) (Review)
- The PPARα-leukotriene B4 pathway to inflammation control: P.R. Devchand, et al.; Nature 384, 39 (1996)
- Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs: J.M. Lehmann, et al.; J. Biol. Chem. 272, 3406 (1997)
- Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta: B.M. Forman, et al.; PNAS 94, 4312 (1997)
- Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators: B. Staels, et al.; Nature 393, 790 (1998)
- Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48: D. Lindén, et al.; J. Biol. Chem. 277, 23044 (2002)
- Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart: B.N. Finck & D.P. Kelly; J. Mol. Cell Cardiol. 34, 1249 (2002) (Review)
- WY-14643 and 9- cis-retinoic acid induce IRS-2/PI 3-kinase signalling pathway and increase glucose transport in human skeletal muscle cells: differential effect in myotubes from healthy subjects and Type 2 diabetic patients: K. Bouzakri, et al.; Diabetologia 47, 1314 (2004)
- Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643: M. Collino, et al.; Free Radic. Biol. Med. 41, 579 (2006)
- Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643: P. Zahradka; Cardiovasc. Drug Rev. 25, 99 (2007) (Review)
- PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators; F.J. Gonzalez & Y.M. Shah; Toxicology 246, 2 (2008)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
